{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:43:25Z","timestamp":1747172605329,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.yebeh.2024.109942","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:35:24Z","timestamp":1723145724000},"page":"109942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Use of artisanal and non-regulated cannabis-based products for the treatment of epilepsy in a low-income population"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5268-1141","authenticated-orcid":false,"given":"Camilo","family":"Espinosa-Jovel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Riveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7192-5869","authenticated-orcid":false,"given":"Angela","family":"Acosta-Amaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-525X","authenticated-orcid":false,"given":"Camila","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109942_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.yebeh.2016.09.040","article-title":"Cannabis and epilepsy: an ancient treatment returns to the fore","volume":"70","author":"Russo","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109942_b0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","article-title":"Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders","volume":"18","author":"Friedman","year":"2019","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2024.109942_b0015","article-title":"Cannabis therapeutics and the future of neurology","volume":"18","author":"Russo","year":"2018","journal-title":"Front Integr Neurosci"},{"key":"10.1016\/j.yebeh.2024.109942_b0020","article-title":"Cannabis-based medicines and the perioperative physician","volume":"8","author":"Tapley","year":"2019","journal-title":"Perioper Med (Lond)"},{"key":"10.1016\/j.yebeh.2024.109942_b0025","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2024.109942_b0030","article-title":"Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations","author":"Espinosa-Jovel","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1016\/j.yebeh.2024.109942_b0035","first-page":"1","article-title":"Epilepsy and cannabidiol: a guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2024.109942_b0040","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2024.109942_b0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.109942_b0050","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2024.109942_b0055","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2024.109942_b0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.109942_b0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2023.09.015","article-title":"Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex","volume":"112","author":"Espinosa-Jovel","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109942_b0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2024.109942_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2024.109942_b0080","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231207755","article-title":"Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2024.109942_b0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.109942_b0090","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.2015.6613","article-title":"Cannabinoid dose and label accuracy in edible medical cannabis products","volume":"313","author":"Vandrey","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2024.109942_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108496","article-title":"Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: a sub-analysis of the 'PELICAN' study","volume":"127","author":"Suraev","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109942_b0100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.nrl.2014.10.016","article-title":"Demographic and social profile of epilepsy in a vulnerable low-income population in Bogot\u00e1, Colombia","volume":"31","author":"Espinosa Jovel","year":"2016","journal-title":"Neurologia"},{"key":"10.1016\/j.yebeh.2024.109942_b0105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109942_b0110","article-title":"Composition and use of cannabis extracts for childhood epilepsy in the Australian community","volume":"8","author":"Suraev","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2024.109942_b0115","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2024.109942_b0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5490","article-title":"Variation in cannabinoid metabolites present in the urine of adults using medical cannabis products in Massachusetts","volume":"4","author":"Gilman","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.yebeh.2024.109942_b0125","unstructured":"US Food and Drug Administration 2016 Warning letters and test results for cannabidiol-related products. https:\/\/www.fda.gov\/newsevents\/publichealthfocus\/ucm484109.htm."},{"key":"10.1016\/j.yebeh.2024.109942_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00359","article-title":"\u03949-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol","volume":"7","author":"Crippa","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2024.109942_b0135","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1039856220965334","article-title":"A systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what's on the label what's in the product?","volume":"29","author":"Oldfield","year":"2021","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.yebeh.2024.109942_b0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/can.2021.0137","article-title":"A clinical framework for evaluating cannabis product quality and safety","volume":"8","author":"MacCallum","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.yebeh.2024.109942_b0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2022.01.001","article-title":"Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy","volume":"95","author":"Caraballo","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109942_b0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2024.109942_b0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.yebeh.2017.02.005","article-title":"An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use","volume":"70","author":"Suraev","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109942_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281040","article-title":"Cannabis use patterns in drug-resistant and pharmacoresponsive epilepsy: single tertiary referral center survey investigation","volume":"18","author":"McDermott","year":"2023","journal-title":"PLoS One"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024003238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024003238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:14:53Z","timestamp":1726373693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024003238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S1525505024003238"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109942","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of artisanal and non-regulated cannabis-based products for the treatment of epilepsy in a low-income population","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109942"}}